Servier announced today that it reached milestones in its osteoarthritis alliance with Galapagos. In July 2010, Servier and Galapagos announced their alliance to develop new medicines for the treatment of osteoarthritis. Galapagos is responsible for the discovery and development of new candidate drugs and Servier has an exclusive option to license these after the completion of Phase I clinical trials by Galapagos.
“We are very pleased with the progress of our alliance with Galapagos so far. This is in line with Servier’s commitment to develop disease-modifying drugs for sufferers of uncured diseases, such as osteoarthritis, a debilitating disease that affects 12% of the world population, leading to severe and costly handicaps,” said Emmanuel Canet, Head of R&D at Servier.
“We are pleased that we reached the first milestones in the osteoarthritis alliance with Servier, just six months after initiating the alliance,” said Onno van de Stolpe, Galapagos’ CEO. “The milestones announced today involve the optimization of molecules that have shown promise in altering the course of osteoarthritis.”
Osteoarthritis (OA) is the most common form of arthritis, typically affecting people aged 45 and older. It is a degenerative disease characterized by joint destruction and loss of cartilage. Cartilage is the slippery tissue that covers the ends of bones in a joint.